U.S. Markets closed

NexImmune, Inc. (NEXI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.67-1.31 (-10.93%)
At close: 4:00PM EDT

NexImmune, Inc.

9119 Gaither Road
Gaithersburg, MD 20877
United States
301 825 9810
http://www.neximmune.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees44

Key Executives

NameTitlePayExercisedYear Born
Mr. Scott P. CarmerPres, CEO & Director518.36kN/A1965
Mr. John Trainer M.B.A.Chief Financial Officer342.44kN/A1974
Ms. Kristi JonesChief Operating Officer397.48kN/A1963
Dr. Jeffrey S. WeberChief Scientific Advisor & Chairman of Scientific Advisory BoardN/AN/AN/A
Mr. Chad RubinSr. VP of Corp. AffairsN/AN/AN/A
Dr. Mathias OelkeSr. VP of Preclinical Immunotherapy & Head of Cell BiologyN/AN/AN/A
Dr. Daniel P. BednarikSr. VP of Molecular Engineering & Protein DesignN/AN/AN/A
Dr. Jerome Bernard ZeldisExec. VP of R&DN/AN/A1950
Dr. Robert Douglas Knight M.D.Chief Medical OfficerN/AN/A1951
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

NexImmune, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.